JP2002531488A - 揮発性液体薬剤を送出するための経皮パッチ - Google Patents
揮発性液体薬剤を送出するための経皮パッチInfo
- Publication number
- JP2002531488A JP2002531488A JP2000586306A JP2000586306A JP2002531488A JP 2002531488 A JP2002531488 A JP 2002531488A JP 2000586306 A JP2000586306 A JP 2000586306A JP 2000586306 A JP2000586306 A JP 2000586306A JP 2002531488 A JP2002531488 A JP 2002531488A
- Authority
- JP
- Japan
- Prior art keywords
- nicotine
- mecamylamine
- drug
- layer
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 229940079593 drug Drugs 0.000 title claims abstract description 62
- 239000007788 liquid Substances 0.000 title claims abstract description 15
- 239000010410 layer Substances 0.000 claims abstract description 90
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 83
- 229960002715 nicotine Drugs 0.000 claims abstract description 81
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 81
- 239000013464 silicone adhesive Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000003522 acrylic cement Substances 0.000 claims abstract description 19
- 230000001419 dependent effect Effects 0.000 claims abstract description 13
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 claims description 64
- 229960002525 mecamylamine Drugs 0.000 claims description 64
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 54
- 239000000853 adhesive Substances 0.000 claims description 22
- 230000001070 adhesive effect Effects 0.000 claims description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 18
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 18
- 229960003946 selegiline Drugs 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 238000009792 diffusion process Methods 0.000 claims description 7
- 206010057852 Nicotine dependence Diseases 0.000 claims description 6
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000779 smoke Substances 0.000 claims description 5
- 238000010030 laminating Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 26
- 239000002131 composite material Substances 0.000 description 23
- 229920001296 polysiloxane Polymers 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 239000012790 adhesive layer Substances 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 230000000391 smoking effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229920000728 polyester Polymers 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000004907 flux Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- -1 polysiloxanes Polymers 0.000 description 6
- 230000005586 smoking cessation Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 238000003475 lamination Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- AQCRXZYYMOXFAN-UHFFFAOYSA-N 2-(1-methyl-2-pyrrolidinyl)-pyridine Chemical compound CN1CCCC1C1=CC=CC=N1 AQCRXZYYMOXFAN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229940087496 habitrol Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940065472 octyl acrylate Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940124535 smoking cessation aid Drugs 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11128598P | 1998-12-07 | 1998-12-07 | |
| US60/111,285 | 1998-12-07 | ||
| PCT/US1999/028697 WO2000033812A2 (en) | 1998-12-07 | 1999-12-07 | Transdermal patch for delivering volatile liquid drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002531488A true JP2002531488A (ja) | 2002-09-24 |
| JP2002531488A5 JP2002531488A5 (enExample) | 2006-12-28 |
Family
ID=22337613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586306A Pending JP2002531488A (ja) | 1998-12-07 | 1999-12-07 | 揮発性液体薬剤を送出するための経皮パッチ |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1137406B2 (enExample) |
| JP (1) | JP2002531488A (enExample) |
| KR (1) | KR100885235B1 (enExample) |
| AT (1) | ATE264098T1 (enExample) |
| AU (1) | AU778992B2 (enExample) |
| CA (1) | CA2380391A1 (enExample) |
| DE (1) | DE69916492T3 (enExample) |
| NZ (2) | NZ525878A (enExample) |
| WO (1) | WO2000033812A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1749521A1 (en) | 2005-08-01 | 2007-02-07 | Nitto Denko Corporation | Production method of nicotine transdermal preparation |
| JP2007509951A (ja) * | 2003-10-28 | 2007-04-19 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 経皮的なドラッグデリバリーシステムにおける医薬品の損失及び送達を制御するための組成物及び方法 |
| US8506991B2 (en) | 2005-10-13 | 2013-08-13 | Nitto Denko Corporation | Nicotine transdermal preparation and production method thereof |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| ATE288256T1 (de) | 1999-01-14 | 2005-02-15 | Noven Pharma | Dermale zusammensetzungen |
| US20030170195A1 (en) | 2000-01-10 | 2003-09-11 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
| WO2002064162A2 (en) | 2001-02-13 | 2002-08-22 | Government Of The United States, As Represented By The Secretary Of The Army | Vaccine for transcutaneous immunization |
| DE10110391A1 (de) | 2001-03-03 | 2002-09-26 | Lohmann Therapie Syst Lts | Hochflexibles Nikotin transdermales therapeutisches System mit Nikotin als Wirkstoff |
| EP1381381A1 (en) * | 2001-03-19 | 2004-01-21 | Gregory M. Glenn | Patch for transcutaneous immunization |
| US7099713B2 (en) | 2002-06-28 | 2006-08-29 | Battelle Memorial Institute | Skin conduction and transport systems |
| US20040086551A1 (en) | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| US20070224284A1 (en) | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
| WO2004080446A1 (en) * | 2003-03-14 | 2004-09-23 | Agi Therapeutics Ltd. | Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine |
| US8784874B2 (en) | 2003-09-10 | 2014-07-22 | Noven Pharmaceuticals, Inc. | Multi-layer transdermal drug delivery device |
| ITMI20041697A1 (it) * | 2004-09-03 | 2004-12-03 | Bouty S P A | Sistema terapeutico a rilascio controllato per uso topico in forma di cerotto multistrato |
| WO2006041911A2 (en) | 2004-10-08 | 2006-04-20 | Noven Pharmaceuticals, Inc. | Device transdermal administration of drugs including acrylic polymers |
| US8343538B2 (en) | 2004-10-08 | 2013-01-01 | Noven Pharmaceuticals, Inc. | Compositions and methods for controlling the flux of a drug from a transdermal drug delivery systems |
| DE102006054733A1 (de) | 2006-11-21 | 2008-05-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit |
| CA2733265A1 (en) * | 2008-09-30 | 2010-04-08 | Teikoku Pharma Usa, Inc. | Transdermal extended-delivery donepezil compositions and methods for using the same |
| EP2298277A1 (en) * | 2009-09-09 | 2011-03-23 | Labtec GmbH | Transdermal patch formulation |
| EP2563347B1 (en) * | 2010-04-30 | 2016-10-12 | Teikoku Pharma USA, Inc. | Propynylaminoindan transdermal compositions |
| WO2012129429A2 (en) | 2011-03-24 | 2012-09-27 | Teikoku Pharma Usa, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| EP2776020B1 (en) | 2011-11-09 | 2019-09-11 | Teikoku Seiyaku Co., Ltd. | Methods for the treatment of skin neoplasms |
| KR20150059177A (ko) | 2012-11-02 | 2015-05-29 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 프로피닐아미노인단 경피 조성물 |
| DE102013013397A1 (de) | 2013-08-13 | 2015-03-12 | Epinamics Gmbh | Aerosolspender für transdermal wirkende pharmazeutische Zusammensetzungen |
| DE102013020633A1 (de) | 2013-12-16 | 2015-06-18 | Epinamics Gmbh | Dermale und/oder transdermale pharmazeutische Zusammensetzung enthaltend eine terpenoide Verbindung |
| DE102020112143B4 (de) | 2020-05-05 | 2022-03-17 | Lts Lohmann Therapie-Systeme Ag | Nicotin - Corona |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63258817A (ja) * | 1987-04-02 | 1988-10-26 | チバ−ガイギー アクチェンゲゼルシャフト | 活性成分の組合せのための経皮的治療システム |
| JPH09509960A (ja) * | 1994-03-07 | 1997-10-07 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
| JPH09301853A (ja) * | 1996-05-14 | 1997-11-25 | Nitto Denko Corp | 貼付剤および貼付製剤 |
| JPH09511987A (ja) * | 1994-01-07 | 1997-12-02 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 溶解度増強剤としてポリビニルピロリドンを含む経皮部材 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4717568A (en) * | 1985-08-09 | 1988-01-05 | Alza Corporation | Laminar arrangement for increasing delivery of beneficial agent from dispenser |
| US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| DE3629304A1 (de) † | 1986-08-28 | 1988-03-24 | Lohmann Gmbh & Co Kg | Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| GB8807504D0 (en) † | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| DE3908432A1 (de) * | 1989-03-14 | 1990-09-27 | Lohmann Therapie Syst Lts | Pflaster als therapeutisches system zur verabreichung von wirkstoffen an die haut mit einer abgestuften wirkstoffabgabe, verfahren zu seiner herstellung sowie verwendung |
| DE3910543A1 (de) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung |
| EP0708627B1 (en) † | 1993-07-09 | 2000-02-02 | Cygnus, Inc. | Method and device for providing nicotine replacement therapy transdermally/transbuccally |
| DE4332094C2 (de) † | 1993-09-22 | 1995-09-07 | Lohmann Therapie Syst Lts | Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung |
| JPH11506744A (ja) * | 1995-06-07 | 1999-06-15 | ノウブン ファーマシューティカルズ インク． | 室温で液体である低分子量薬を含む経皮組成物 |
| US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
-
1999
- 1999-12-07 NZ NZ52587899A patent/NZ525878A/xx not_active IP Right Cessation
- 1999-12-07 AT AT99968461T patent/ATE264098T1/de not_active IP Right Cessation
- 1999-12-07 NZ NZ512788A patent/NZ512788A/en not_active IP Right Cessation
- 1999-12-07 JP JP2000586306A patent/JP2002531488A/ja active Pending
- 1999-12-07 WO PCT/US1999/028697 patent/WO2000033812A2/en not_active Ceased
- 1999-12-07 DE DE69916492T patent/DE69916492T3/de not_active Expired - Lifetime
- 1999-12-07 CA CA002380391A patent/CA2380391A1/en not_active Abandoned
- 1999-12-07 KR KR1020017007132A patent/KR100885235B1/ko not_active Expired - Fee Related
- 1999-12-07 EP EP99968461A patent/EP1137406B2/en not_active Expired - Lifetime
- 1999-12-07 AU AU25877/00A patent/AU778992B2/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63258817A (ja) * | 1987-04-02 | 1988-10-26 | チバ−ガイギー アクチェンゲゼルシャフト | 活性成分の組合せのための経皮的治療システム |
| JPH09511987A (ja) * | 1994-01-07 | 1997-12-02 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 溶解度増強剤としてポリビニルピロリドンを含む経皮部材 |
| JPH09509960A (ja) * | 1994-03-07 | 1997-10-07 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
| JPH09301853A (ja) * | 1996-05-14 | 1997-11-25 | Nitto Denko Corp | 貼付剤および貼付製剤 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6010004687, ＲＯＳＥ， Ｊ． Ｅ． ｅｔ ａｌ．, ＣＬＩＮＩＣＡＬ ＴＲＩＡＬＳ ＡＮＤ ＴＨＥＲＡＰＥＵＴＩＣＳ, 1994, Ｖｏｌ．５６， Ｎｏ．１, ｐ．８６−９９ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509951A (ja) * | 2003-10-28 | 2007-04-19 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 経皮的なドラッグデリバリーシステムにおける医薬品の損失及び送達を制御するための組成物及び方法 |
| EP1749521A1 (en) | 2005-08-01 | 2007-02-07 | Nitto Denko Corporation | Production method of nicotine transdermal preparation |
| US8506991B2 (en) | 2005-10-13 | 2013-08-13 | Nitto Denko Corporation | Nicotine transdermal preparation and production method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010101147A (ko) | 2001-11-14 |
| EP1137406B2 (en) | 2008-01-23 |
| NZ512788A (en) | 2003-07-25 |
| DE69916492T3 (de) | 2008-08-14 |
| KR100885235B1 (ko) | 2009-02-24 |
| WO2000033812A2 (en) | 2000-06-15 |
| DE69916492T2 (de) | 2005-05-12 |
| AU2587700A (en) | 2000-06-26 |
| DE69916492D1 (de) | 2004-05-19 |
| WO2000033812A3 (en) | 2000-11-23 |
| EP1137406A2 (en) | 2001-10-04 |
| NZ525878A (en) | 2004-12-24 |
| EP1137406B1 (en) | 2004-04-14 |
| AU778992B2 (en) | 2004-12-23 |
| ATE264098T1 (de) | 2004-04-15 |
| CA2380391A1 (en) | 2000-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002531488A (ja) | 揮発性液体薬剤を送出するための経皮パッチ | |
| US6974588B1 (en) | Transdermal patch for delivering volatile liquid drugs | |
| EP0708627B1 (en) | Method and device for providing nicotine replacement therapy transdermally/transbuccally | |
| JP5938612B2 (ja) | 経皮吸収治療システム | |
| CN1187106C (zh) | 双重粘合剂经皮药物释放系统 | |
| WO2000033812A9 (en) | Transdermal patch for delivering volatile liquid drugs | |
| US20110091511A1 (en) | Transdermal delivery of drugs based on crystal size | |
| JPS6214526B2 (enExample) | ||
| US8784874B2 (en) | Multi-layer transdermal drug delivery device | |
| JP2002531488A5 (enExample) | ||
| WO2004041324A2 (en) | Transdermal delivery of fentanyl | |
| JPH08508266A (ja) | 皮膚へのエストラジオール放出用活性物質パッチ | |
| EP1449527A2 (en) | Transdermal patch for administering a volatile liquid drug | |
| KR100439659B1 (ko) | 툴로부테롤을 함유하는 경피흡수용 패취제 | |
| AU2003254834B2 (en) | Female hormone-containing patch | |
| HUP0104950A2 (en) | Composition containing glycerol trinitrate, method for producing said composition and use of the same | |
| WO2006024339A2 (en) | Controlled-release multilayer patch for the topical use | |
| HK1075816B (en) | Transdermal delivery of fentanyl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061108 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061108 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100430 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100512 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100602 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100609 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100907 |